{"id":"W2061147448","doi":"10.1016/s0828-282x(09)70136-9","title":"A multicentre, randomized, double-blind placebo-controlled trial evaluating rosiglitazone for the prevention of atherosclerosis progression after coronary artery bypass graft surgery in patients with type 2 diabetes. Design and rationale of the VeIn-Coronary aTherOsclerosis and Rosiglitazone after bypass surgerY (VICTORY) trial","year":2009,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Peroxisome Proliferator-Activated Receptors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":16,"is_retracted":false,"has_abstract":false,"ca_institutions":"McMaster University; Queen Elizabeth II Health Sciences Centre; Toronto General Hospital; Hôpital Notre-Dame; Centre Hospitalier de l’Université de Montréal","funders":"Université Laval; Sanofi; GlaxoSmithKline","keywords":"Medicine; Rosiglitazone; Type 2 diabetes; Placebo; Randomized controlled trial; Artery; Coronary artery bypass surgery; Internal medicine; Diabetes mellitus; Surgery; Cardiology; Endocrinology; Insulin; Alternative medicine; Pathology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":true,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001703446,0.002072203,0.003783849,0.0004149701,0.0006730417,0.00112183,0.001031841,0.002467283,0.007432963],"category_scores_gemma":[0.002462147,0.0007435551,0.00171748,0.0004147589,0.001036583,0.0008515421,0.0005664015,0.002541974,0.00116719],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006885838,"about_ca_system_score_gemma":0.001258949,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001658612,"about_ca_topic_score_gemma":0.003654962,"domain_scores_codex":[0.9992015,0.0004093567,0.00005571372,0.0001563001,0.00006320138,0.0001138476],"domain_scores_gemma":[0.9993,0.0001685106,0.0001513567,0.00006759699,0.00006855738,0.0002438459],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.990987,0.001639694,0.0003169241,0.0005221588,0.0009300138,0.00002137801,0.0000217638,0.0001030919,0.000939596,0.00010221,0.0004738933,0.003942313],"study_design_scores_gemma":[0.990533,0.00803697,0.0006439827,0.00001731712,0.0003561658,0.000009345887,0.000007627985,0.00008610044,0.00006561498,0.00005856351,0.0001804016,0.000004971171],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"protocol","genre_scores_codex":[0.9709219,0.01006196,0.001032935,0.001783801,0.001895219,0.008916474,0.001916632,0.000218753,0.003252426],"genre_scores_gemma":[0.9756191,0.004336232,0.002485882,0.002156392,0.0009368805,0.008139413,0.001605649,0.00003108111,0.004689288],"genre_candidate":"protocol","genre_consensus":null,"teacher_disagreement_score":0.007432963,"threshold_uncertainty_score":0.02486575,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02436367529001012,"score_gpt":0.251889146231977,"score_spread":0.2275254709419669,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}